Low-Dose Atropine Not FDA Approved: What the STAR Study Means for Today’s Myopia Control Practices

The topic of low-dose atropine, not FDA-approved, has become one of the most important conversations in pediatric eye care this year, especially as clinicians turn to the STAR Study for clarity on atropine’s role in modern myopia control. The STAR Study is the largest and most ethnically diverse atropine study to date, evaluating 0.01% and 0.03% atropine versus placebo in more than 800 children across three countries.

There are no comments yet.

Please log in to write the first comment.